RBEHomo sapiens (Human)Cancer cell line
Also known as: RBA
🤖 AI SummaryBased on 3 publications
Quick Overview
Human intrahepatic cholangiocarcinoma cell line with IDH mutations and dasatinib hypersensitivity.
Detailed Summary
The RBE cell line is a human intrahepatic cholangiocarcinoma (ICC) cell line derived from a patient with a cholangiocarcinoma that exhibited sarcomatous change. It is known for its IDH1 mutation (R132S) and demonstrates high sensitivity to the multi-kinase inhibitor dasatinib. Research has shown that RBE cells are part of a subset of ICC with IDH mutations that exhibit a unique dependency on SRC signaling, making them highly responsive to dasatinib treatment. This cell line has been used in studies to explore the therapeutic potential of targeting SRC in IDH mutant ICC, as well as to investigate the molecular mechanisms underlying dasatinib hypersensitivity. Additionally, RBE cells have been utilized in in vitro and in vivo models to study tumor growth and response to various chemotherapeutic agents.
Research Applications
Investigation of IDH1 mutations and their role in cancer progressionEvaluation of dasatinib sensitivity in IDH mutant ICCStudy of SRC dependency in IDH mutant ICCIn vitro and in vivo tumor growth modeling
Key Characteristics
IDH1 R132S mutationHigh sensitivity to dasatinibSRC dependency for survival and proliferationUse in drug screening and mechanism of action studies
Generated on 6/21/2025
Basic Information
| Database ID | CVCL_4896 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Liver[UBERON:UBERON_0002107] |
Donor Information
| Age | 64 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Cholangiocarcinoma |
|---|---|
| Lineage | Biliary Tract |
| Subtype | Intrahepatic Cholangiocarcinoma |
| OncoTree Code | IHCH |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-001856_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | KRAS | p.Gly12Val (c.35G>T) | Heterozygous | Acquired | Unknown, Unknown |
| MutationSimple | IDH1 | p.Arg132Ser (c.394C>A) | Unspecified | - | from parent cell line RBE |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
12
D13S317
9
D16S539
10,11
D18S51
13,15
D19S433
14,15.2
D21S11
29
D2S1338
17,24
D3S1358
14,15
D5S818
11,12
D7S820
8,11
D8S1179
13,14
FGA
19,24
Penta D
12
Penta E
18
TH01
6
TPOX
8
vWA
20
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets.
Vazquez F., Getz G., Bardeesy N.M.
bioRxiv 2024:07.04.601970-07.04.601970(2024).
Development and characterization of human primary cholangiocarcinoma cell lines.
Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.
Am. J. Pathol. 192:1200-1217(2022).
Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.
Jirawatnotai S.
Hepatology 70:1614-1630(2019).
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Bardeesy N.M.
Cancer Discov. 6:727-739(2016).
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Yamori T.
Mol. Cancer Ther. 4:399-412(2005).